Related Experiment Video
Updated: Aug 5, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Niosomes loading N-acetyl-L-cysteine for cancer treatment in vivo study
Ebtesam A Mohamad1,2, Abeer A Ali3, Marwa Sharaky4
1Department of Biophysics, Faculty of Science, Cairo University, 12613, Giza, Egypt.
Abstract:
Scientists are seeking to find an effective treatment for tumors that has no side effects. N-Acetyl-l-cysteine (NAC) is a thiol compound extracted from garlic. Current study explores the potential of NAC-loaded niosomes (NAC-NIO) for tumor treatment in mice. NAC-loaded niosomes' efficiency, morphology, UV absorption, size distribution, zeta potential, release, and FTIR analysis were evaluated. For vivo study, 25 male BALB/c mice were divided to five groups: gp1 negative control (receive saline), gp2 positive control (tumor group), gp3 treated with NAC, gp4 treated with NAC-NIO at the same time of tumor injection, and gp5 treated with NAC-NIO after tumor growth (day 14). The impact of NAC-NIO on the tumor treatment was evaluated by measuring tumor size progress, comet assay, oxidative stress parameters (GSH, nitric oxide, MDA), western blot analysis, and histopathological investigation of tissues. NAC-NIO showed 72 ± 3% encapsulation efficiency and zeta potential - 5.95 mV with spherical shape. It was found that oral administration of NAC-NIO in a dose of 50 mg/kg provided significant protection against tumor cells. Our formulation decreases DNA injury significantly (P < 0.05). It was noticed that NAC-NIO can increase oxidative stress levels in tumor tissue. On the other hand, the caspase 3 and caspase 9 gene expression were upregulated significantly (P < 0.001) in mice administrated NAC-NIO compared with all other groups. Histological studies confirmed the protective effect of NAC-NIO against tumor especially for treatment during tumor growth protocol. The results suggested that oral delivery of NAC-NIO formulation improved antioxidant effect.
Insights
N-Acetyl-l-cysteine niosomes (NAC-NIO) show promise for tumor treatment by reducing DNA damage and increasing oxidative stress. Oral administration of NAC-NIO demonstrated significant anti-tumor effects in mice, suggesting a potential new therapeutic strategy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Pharmacology
Background:
- Tumor treatment seeks effective, side-effect-free therapies.
- N-Acetyl-l-cysteine (NAC), a garlic-derived thiol, is explored for therapeutic potential.
- Niosomes offer a promising drug delivery system for enhanced therapeutic efficacy.
Purpose of the Study:
- To evaluate N-Acetyl-l-cysteine-loaded niosomes (NAC-NIO) for tumor treatment in a mouse model.
- To assess the physicochemical properties and in vivo efficacy of NAC-NIO.
- To investigate the impact of NAC-NIO on tumor progression, DNA damage, oxidative stress, and apoptosis.
Main Methods:
- Characterization of NAC-NIO (encapsulation efficiency, zeta potential, morphology, size, FTIR).
- In vivo study involving BALB/c mice divided into control and treatment groups (NAC, NAC-NIO).
- Evaluation of tumor size, comet assay, oxidative stress markers (GSH, nitric oxide, MDA), western blot (caspase 3 & 9), and histopathology.
Main Results:
- NAC-NIO exhibited 72±3% encapsulation efficiency and a zeta potential of -5.95 mV, with a spherical shape.
- Oral NAC-NIO (50 mg/kg) significantly protected against tumor cells, reducing DNA damage (P<0.05).
- NAC-NIO upregulated caspase 3 and caspase 9 gene expression (P<0.001) and increased oxidative stress in tumor tissue, with histological studies confirming protective effects.
Conclusions:
- Oral delivery of NAC-NIO formulation demonstrates significant anti-tumor activity in mice.
- NAC-NIO effectively reduces DNA damage and induces apoptosis in tumor cells.
- The developed NAC-NIO formulation represents a potential strategy for improved tumor treatment with enhanced antioxidant effects.
More Related Videos
07:59A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018